Andrew Zannettino

Professor Andrew Zannettino

Interim Executive Dean

Health and Medical Sciences Faculty Office

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.


Andrew Zannettino is the Associate Dean of Research and Professor of Experimental Haematology in the Faculty of Health Sciences, University of Adelaide and heads the Myeloma Research Laboratory (MRL) and co-heads the Regenerative Medicine Program (RMP).

The MRL’s efforts centre on identifying the molecular and cellular mechanisms responsible for myeloma disease progression and myeloma-associated bone loss.

The RMP stems from collaborative studies in association with Prof Stan Gronthos (Mesenchymal Stem Cell Laboratory, University of Adelaide) and Prof Paul Simmons (Mesoblast Ltd), which led to the patenting of technologies covering the identification and isolation of Mesenchymal Precursor Cells (MPC), a rare cell population present in many post-natal tissues.

The family of 8 patents surrounding this technology underpin the world’s largest cell therapy company, Mesoblast Ltd.

Research Interests

Myeloma is haematological malignancy characterised by the clonal proliferation of plasma cells, an immune cell type that normally protects us against infection. Myeloma is the second most common blood cancer and more than 100,000 people are diagnosed each year worldwide. Despite recent advances in treatment, myeloma remains almost universally fatal and has a 10-year survival rate of approximately 17%. The main clinical manifestations of myeloma are the development of osteolytic bone lesions, bone pain, hypercalcaemia, renal insufficiency, suppressed immunoglobulin production and increased bone marrow angiogenesis (blood vessel formation). Myeloma is preceded by a premalignant (asymptomatic) monoclonal gammopathy of uncertain significance (MGUS) stage. The factors that trigger the progression from MGUS to myeloma remain to be determined; however, our studies show that both intrinsic genetic changes and extrinsic factors play a role in disease progression. Our laboratory’s research is focussed on detecting the key signalling pathways that are deregulated during disease development and determining what microenvironmental changes occur during disease pathogenesis. We believe that these approaches will enable us to identify new molecular markers of disease risk and to design drugs against novel therapeutic targets.

Current projects are focused on
  • Identifying the genetic, transcriptional and epigenetic changes that trigger the progression from asymptomatic MGUS to myeloma
  • Determining why the bone marrow is a “hot-spot” for myeloma plasma cell metastasis
  • Identifying the mechanisms governing dissemination and relapse in multiple myeloma
  • Identifying the role played by the newly described tumour suppressor genes GLIPR1 and SAMSN1 in multiple myeloma development
  • Determining the effects of myeloma plasma cells on mesenchymal stem cell differentiation.
  • Assessing the effectiveness of targeting class IIa histone deacetylases (HDAC) to treat myeloma and myeloma-associated bone disease
  • Identifying the role of the mTOR pathway in mesenchymal stem cell biology and bone formation.
  • Assessing the effectiveness of targeting skeletal mTORC1 as a novel approach to treat diet-induced insulin resistance
Research Leadership

I provide research leadership as Associate Dean (Research), Faculty of Health Science and Laboratory Leader, Myeloma Research Laboratory, Cancer Theme, SAHMRI. As detailed herein, I also provide research leadership as a board member of a number of Institutes and Centres, member of the Assigners Academy of the NHMRC and committee member of the Medical and Scientific Advisory Group of the Australian Myeloma Foundation.

Myeloma and Bone Cancer Research

Multiple myeloma is an incurable haematological cancer of the antibody-producing plasma cell. Myeloma is unique amongst haematological malignancies in its capacity to cause massive destruction of the skeleton. The Myeloma Research Laboratory’s (MRL) efforts centre on identifying the molecular and cellular mechanisms responsible for myeloma disease progression (https://www.sahmri.com/our-research/themes/cancer/groups/mel-test-group).

Myeloma is haematological malignancy characterised by the clonal proliferation of plasma cells, an immune cell type that normally protects us against infection. Myeloma is the second most common blood cancer and more than 100,000 people are diagnosed each year worldwide. Despite recent advances in treatment, myeloma remains almost universally fatal and has a 10-year survival rate of approximately 17%. The main clinical manifestations of myeloma are the development of osteolytic bone lesions, bone pain, hypercalcaemia, renal insufficiency, suppressed immunoglobulin production and increased bone marrow angiogenesis (blood vessel formation). Myeloma is preceded by a premalignant (asymptomatic) monoclonal gammopathy of uncertain significance (MGUS) stage. The factors that trigger the progression from MGUS to myeloma remain to be determined; however, our studies show that both intrinsic genetic changes and extrinsic factors play a role in disease progression. Our laboratory’s research is focussed on detecting the key signalling pathways that are deregulated during disease development and determining what microenvironmental changes occur during disease pathogenesis. We believe that these approaches will enable us to identify new molecular markers of disease risk and to design drugs against novel therapeutic targets.

The MRL has made a significant contribution to the field in relation to
  • Mechanisms of myeloma associated bone loss
  • Identifying the genetic, transcriptional and epigenetic changes that trigger the progression from asymptomatic MGUS to myeloma
  • Determining why the bone marrow is a “hot-spot” for myeloma plasma cell metastasis
  • Identifying the mechanisms governing dissemination and relapse in multiple myeloma
  • ​Identifying the role played by the newly described tumour suppressor genes GLIPR1 and SAMSN1 in multiple myeloma development
  • Identifying how myeloma plasma cells affect mesenchymal stem cell differentiation.
  • The effectiveness of targeting class IIa histone deacetylases (HDAC) to treat myeloma and myeloma-associated bone disease
  • Identifying a role for the mTOR pathway in mesenchymal stem cell biology and bone formation.
  • Assessing the effectiveness of targeting skeletal mTORC1 as a novel approach to treat diet-induced insulin resistance
Therapeutic Use of Mesenchymal Progenitor Cells

Mesenchymal Progenitor Cells (MPC) are rare stem cells present within post-natal tissues which possess promising therapeutic properties. In the late 90’s, collaborative studies in association with Prof Stan Gronthos (Mesenchymal Stem Cell Laboratory, UA/SAHMRI) and Professor Paul Simmons (Mesoblast Ltd.) led to the patenting of technologies covering the identification and isolation of these rare cells from bone marrow. The family of 8 patents surrounding this technology were assigned to Angioblast Systems Inc., New York, USA in November, 2004 facilitating the formation of Mesoblast Ltd, an Australian Stock Exchange listed company (http://www.mesoblast.com). In return for the assignment of these patents, the IMVS/Medvet/SA Pathology (my substantive employer at that time) received a significant parcel of shares in this company. Since January 2005, Prof Gronthos and I have served as consultants to both Angioblast Systems Inc. and Mesoblast Ltd. and our laboratories have continued to receive funding to support the improvement/development of existing/new intellectual property and to fund large pre-clinical animal models of disease.

Research Collaborations

My expertise in the fields described above has led to active collaborations with scientists/clinicians throughout the world as detailed below.

In 1994-1995, I developed a powerful retroviral-based expression cloning strategy to enable isolation of genes encoding cell surface molecules that participate in intercellular interactions. This methodology has lead to numerous collaborations and ongoing consultation work with scientists including:

  • Dr H-J. Buhring, University of Tubingen, Germany, Retroviral Expression cloning of cell surface antigens expressed by normal and leukaemic haemopoietic stem cells;
  • Prof. Leonie K. Ashman, University of Newcastle, Retroviral Expression cloning of drug resistance genes;
  • Prof. James T. Triffit, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Centre, Oxford, UK, Retroviral Expression cloning of osteoblast-related cell surface antigens;
  • Dr S. Watt, MRC Molecular Haematology Unit, The Institute of Molecular Medicine, University of Oxford, UK, Retroviral Expression cloning of novel cell surface molecules.

My research into myeloma-associated bone loss and molecular mechanisms of myeloma disease pathogenesis has led to further collaborations with a number of academic and industry-based scientists including:

  • Prof. John Shaughnessy, Formerly of University of Arkansas, Little Rock, Arkansas, USA and founder of SignalGeneticsTM, Carlsbad, CA.  The role of DKK-1 in myeloma-associated bone loss;
  • Dr Daniel Peet, Department of Bichemistry, Molecular Life Sciences, University of Adelaide: Role of CXCL12 (SDF-1)/CXCR4 in Pathological Angiogenesis and Osteolytic Bone Disease in Multiple Myeloma;
  • Dr Phil Kearney, Santaris Pharma, Copenhagen, Denmark: Role of CXCL12 (SDF-1)/CXCR4 in Pathological Angiogenesis and Osteolytic Bone Disease in Multiple Myeloma;
  • Prof. Nobutaka Fujii and Prof. Hirokazu Tamamura, Graduate School of Pharmaceutical Sciences Kyoto University Department of Bioorganic Medicinal Chemistry, JAPAN, Role of SDF-1 in myeloma;
  • A/Prof. Kevin Lynch, Novartis, Sydney, Australia, Tyrosine Kinase Inhibition as a Potential Modality to Control Osteolytic Bone Disease: A New Role for Imatinib Mesylate and Second Generation Bcr-Abl Inhibitors;
  • Dr Elisabeth Buchdunger and Dr Paul Manley, Novartis Pharma, Skeletal Effects of the Abl Kinase Inhibitors, Nilotinib and Imatinib;
  • Dr Francis Lee and Dr Richard Smykla, Bristol-Myers Squibb, Skeletal Effects of the Abl Kinase Inhibitors, Dasatinib;
  • Prof. Vijay Modur, Novartis Pharmaceuticals Corporation, Cambridge, MA, USA. Novel mediators of multiple myeloma metastases to the bone;
  • Prof. William Dougall, Amgen, Seattle, Washington, USA, The role of RANKL in myeloma-associated bone loss;
  • Prof. Peter Croucher, Bone Biology Laboratory, Bone Biology Division, Garvan Institute of Medical Research, NSW, AUS. The role of the bone marrow microenvironment in the pathogenesis of myeloma;
  • Dr Daniel Worthley, University of Adelaide, Adelaide, Australia, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
  • Prof. Siddhartha Mukherjee, Columbia University, NY, USA. The role of the bone marrow microenvironment in the pathogenesis of myeloma;
  • Prof. Orest Blaschuk, Urology Research Laboratories, Division of Urology, McGill University Health Centre, Canada. The use of Cadherin antagonists to treat multiple myeloma;
  • Prof. Jonathan Licht, University of Florida Cancer Centre. The role of EMT in myeloma disease dissemination and disease progression;
  • Prof. Ricky Johnstone, Gene Regulation Laboratory, Peter MacCallum Cancer Centre, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
  • Associate Professor Simon Leedham, Wellcome Trust Centre for Human Genetics, Oxford, The role of the bone marrow microenvironment in the pathogenesis of myeloma;
  • Prof. Charles Mullighan, Hematological Malignancies Program, St. Jude Children’s Research Hospital, Understanding clonal evolution in multiple myeloma;
  • Prof. Gareth Morgan, University of Arkansas, Myeloma Institute for Research and Therapy (UAMS), Understanding clonal evolution in multiple myeloma.

My research into physiological and aberrant bone remodelling and novel skeletally-derived factors that regulate glucose metabolism has led to collaborations with a number of academic and industry-based scientists including:

  • Prof. D.M. Findlay and Dr Gerald J. Atkins and Dr. Andreas Evdokiou, Discipline of Orthopaedics and Trauma, Royal Adelaide Hospital and the University of Adelaide. Normal and pathological bone remodelling;
  • Dr. Andreas Evdokiou, Discipline of Surgery, Basil Hetzel Institute for Translational Health Research and the University of Adelaide. Bone cancer and bone cancer metastasis;
  • Dr Colin Dunstan, University of Sydney and formerly of Amgen Inc, CA, USA; The Role of OPG in bone metabolism;
  • Dr Peter J Anderson and Prof David David, Child Health Research Institute and The Women’s and Childrens Hospital, Adelaide, South Australia: Mechanisms of premature cranial fusion and development of novel adjunct approaches to treatment;
  • Prof H. Zreiqat, School of Pathology, University of New South Wales, Sydney, Australia, Behaviour of osteoclasts and bone cells on bio-material surfaces;
  • Prof D. R. Haynes, Department of Pathology, University of Adelaide, Adelaide, South Australia, The role of TNF family members TWEAK and TNF-alpha in bone remodelling;
  • A/Prof Sofianos Andrikopoulos, The University of Melbourne, The University of Melbourne, Skeletal endocrine signalling in the regulation of glucose metabolism;
  • Dr Paul Baldock, Garvan Institute of Medical Research, Garvan Institute of Medical Research, The University of New South Wales, Skeletal endocrine signalling in the regulation of glucose metabolism;
  • Prof Christopher Proud, South Australian Health and Medical Research Institute, SA, AUS, Targeting skeletal mTORC1 as a novel approach for the treatment of diet-induced insulin resistance.

My research into mesenchymal precursor cell biology and application has led to collaborations with a number of biotechnology companies, including Angioblast Systems Inc., Mesoblast Ltd. and Genzyme International. In addition, I also collaborate and consult for a number of academic scientists including:

  • Prof. Silviu Itescu, University of Melbourne and Columbia University's New York -Presbyterian Hospital in New York, USA and Angioblast Systems Inc and Mesoblast Ltd.: Clinical Application of Mesenchymal Precursor Cells for bone repair, articular cartilage regeneration, disc cartilage regeneration, cellular therapy of heart attack/heart failure, peripheral arterial disease and wound ulcers;
  • A/Prof. Robert Moore, Formerly head of the Adelaide Centre for Spinal Research, Institute of Medical and Veterinary Science, Adelaide, South AUSTRALIA: A Preclinical trial of the potential for cultured mesenchymal precursor cells to restore extracellular matrix and normal mechanical function to degenerate intervertebral discs;
  • Prof. Peter Ghosh, Institute of Nutraceutical Research, Brookevale, NSW, Australia: Cartilage Regenerative Potential of Ovine Mesenchymal Precursor Cells (MPC);
  • A/Prof John Field, Flinders University of South Australia, School of Medicine, Bedford Park, South Australia: Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPC) for the repair of critical size defects in an ovine tibial model;
  • Prof. Stephen Worthley, Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, South Australia: A study of the cardiac regenerative potential of immunoselected ovine bone marrow mesenchymal stem cells;
  • Dr Cory Xian and Prof. Bruce Foster, Bone Growth Foundation, Department of Orthopaedic Surgery, Women's and Children's Hospital. Molecular pathways for the bony repair of injured growth plate cartilage;
  • Prof. Richard Read, Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPCs) in the regeneration of a medial knee joint meniscus and the retardation of cartilage injury in an ovine model of osteoarthritis;

Since 2005, I have been a scientific consultant for Mesoblast Ltd. where I have helped consolidate and expand our stem cell based technology patent family and have successful completed key milestones such as the development of a MSC isolation and culture expansion standard operational protocol within a GMP facility. This has resulted in an increase in capital investor funding to support the commencement of several phase II/III cardiac and orthopaedic clinical studies. Funds from Mesoblast Ltd have been used to continue basic R&D in our laboratory and for initiating new pre-clinical animal studies within the IMVS/ Hanson Institute/ RAH/ University of Adelaide campuses. Collectively, these studies have formed the foundation of new IND (investigative new drug) applications submissions to the USA FDA for future phase I/II/III human clinical trials involving different health centres and laboratories in Adelaide, Australia and the USA.

Research Output

I have co-authored more than 177 refereed publications, book chapters and review articles (not including published abstracts). Many of these articles are published in premier Haematology and Orthopaedic journals (BLOOD, Leukemia, BJH, JBMR, Bone), Cancer journals (Cancer Research, Clinical Cancer Research) and Stem Cell journals (Cell Stem Cell, Stem Cells). My publications have received in excess of 9800 citations and his H Factor = 51. Refer to Publications section for full details.

Presentations

I have has been invited to present my laboratory’s findings at more than 40 national and international forums since 2010. In addition, I have co-authored more than 75 abstracts with more than 55 of these being published as Meeting Proceedings.

Year National/ International Event Title Role
Conference Presentations

2016

National

New Directions in Leukaemia Research meeting March 16-19, 2016, Noosa, QLD, AUS

Invited Speaker

2015

International

"PACIFICHEM 2015 Conference December 15-20, 2015 in Honolulu, HI."

Invited Speaker

2014

International

American Society of Haematology

Invited Speaker

2014

National

Sydney Cancer and Bone Meeting

Invited Speaker

2013

International

Australian and New Zealand Bone and Mineral Society

Invited Speaker

2013

National

Frontiers in Skeletal Biology

Invited Speaker

2012

National

Combio 2012

Invited Speaker

2012

National

SA Multiple Myeloma Interest Group

Invited Speaker

2012

National

SVRI-Seminar Series

Invited Speaker

2012

National

The Australian Health and Medical Research Congress

Invited Speaker

2011

International

Austalian and New Zealand Bone and Mineral Research

Plenary Speaker

2010

National

Adelaide Bone Group Meeting

Invited Speaker

2010

International

American Society of Haematology

Session Chair

2010

National

Annual HSANZ - SA “Blood Club Meeting”,

Invited Speaker

2010

National

Leukaemia Foundation of Australia – Myeloma Awareness Day

Invited Speaker

2009

International

Asia Pacific Haematology Summit

Keynote Speaker

2009

International

HAA 2009; 2009 Annual Scientific Meeting of HSANZ, ANZSBT, ASTH

Keynote Speaker

2009

National

Health Development Adelaide Symposium

Presenter

2009

International

Janssen Cilag, Multiple Myeloma 3 (MM3) meeting

Presenter

2009

International

Novartis APECHO-APTM Workshop

Keynote Speaker

2008

International

American Society of Haematology

Poster Presenter

2008

National

Bio Innovation SA Networking Forum – Bio Innovation Osteo Networking Evening

Keynote Speaker

2008

International

Fifth Clare Valley Bone Meeting

Keynote Speaker

2008

National

NCRIS 5.5 CGMP - SEMINAR/WORKSHOP - “NANO-ENGINEERING FOR CELLS”

Presenter

2008

National

Royal Adelaide Hospital Medical Grand Round

Presenter

2007

National

Barbara Ell Seminar Series, Victor Chang Cardiac Research Institute

Presenter

2007

International

Novartis Oncology Research and Development Symposium

Presenter

2007

National

2007 Mater Medical Research Institute Symposium

Presenter

2006

International

American Society of Haematology

Session Chair

2006

National

Department of Orthopaedics and Trauma, Royal Melbourne Hospital

Presenter

2006

National

Inaugural Tissue Engineering Symposium (SuTEN), Biomedical Engineering at Sydney University School of Aerospace, Mechanical and Mechatronic Engineering and The Bosch Institute

Presenter

2006

International

Novartis Oncology Australia, Research and Development Symposium, The Intercontinental Hotel

Keynote Speaker

2005

National

ANZ Matrix Biology Society Conference, Whalers Inn, Victor Harbour, SA

Keynote Speaker

2005

National

Department of Genetic Medicine, Womens and Children’s Hospital

Presenter

2005

National

Division of Molecular Pathology, IMVS

Presenter

2005

National

The Basil Hetzel Institute, The Queen Elizabeth Hospital

Presenter

2004

International

Haematology Society of Australia and New Zealand, Exhibition and Convention Centre

Presenter

2003

National

Adelaide Blood Club

Invited Speaker

2003

National

Division of Clinical Biochemistry, IMVS

Invited Speaker

2003

National

Division of Molecular Pathology, IMVS

Invited Speaker

2003

National

Division of Pathology, IMVS

Invited Speaker

2003

National

The Alfred Hospital

Invited Speaker

2002

International

Australian and New Zealand Orthopaedic Research Society

Invited Speaker

2002

National

Child Health Research Institute

Invited Speaker

2002

National

Department of Medicine, University of Adelaide

Invited Speaker

2002

National

Molecular Biology of Skeleton

Invited Speaker

2001

National

Adelaide Blood Club

Invited Speaker

2001

International

Molecular Mechanisms of Skeletal Disease mediated by Myeloma, NIH

Invited Speaker

2001

International

Zymogenetics

Invited Speaker

1998

International

Australian and New Zealand Orthopaedic Research Society

Invited Speaker

1998

International

Haematology Society of Australia and New Zealand

Invited Speaker

1998

National

Hanson Symposium

Invited Speaker

 

Additional Evidence of Research Leadership

When I joined the UA School of Medical Sciences (SoMS), I served as a member of the Research Committee. In January 2014, I was appointed as Chair of this committee, and immediately instituted 4 new funding programs designed to drive research activity, including an ECR “kick start” award, a strategic equipment fund, an ECR/MCR travel award and a publication award program.

I was also appointed to the SoMS board, the FHS Research Committee and was the Deputy Chair of the Adelaide Medical and Nursing School (AMNS) Project Committee overseeing the construction of a new $230 million Medical/Nursing/Research facility in the new West End Biomedical Research Precinct which will house approximately 350 Researchers. In January 2015, I was appointed to Deputy Head, SoMS.  In March 2015, the Executive Dean, Professor Alastair Burt appointed me to establish and chair the Research Strategy Taskforce (RSTF). The RSTF was charged with the responsibility of devising a new research strategy to promote research excellence within the FHS. This work has led to the development of an adaptable strategic framework to enhance research education (HDR/honours), develop research strengths, build enabling technologies/research infrastructure and develop pathways to improved health care and the generation of valuable intellectual property.

My national standing in the fields of cell and cancer biology has been recognised by my appointment to the NHMRC Grant Review Panel (GRP) for Cell biology (2005, 2006) and Oncology (2010) and Assigners Academy (2014, 2015, 2016). In recognition of my international standing in the field of myeloma-associated bone loss, I was invited by the Leukaemia Research Fund (LRF) of UK, to participate in a “site visit” of Myeloma Program of Prof. Peter Croucher, University of Sheffield, UK, to assess his application for program funding through the LRF in both 2006 and 2009. In addition, I was invited to participate as a moderator for the 2006 American Society of Haematology (ASH) Annual Meeting, for the session titled “Multiple Myeloma: Microenvironment”. Recently, I was invited to be an Abstract Reviewer of the “Myeloma-Pathophysiology and Preclinical studies excluding Therapy” Category for the 52nd Annual Meeting of the ASH, a prestigious appointment bestowed upon recognized experts in the field.

As a testament to my expertise in my chosen fields, I have been asked to present my laboratories findings at numerous scientific meetings and institutions (see “Conference Presentations”) and I have been asked to contribute to numerous review articles and book chapters (see “Publications”). As a recognised expert in the areas of skeletal, stem and cancer biology, I am asked to review >3 manuscripts per month for more that 20 journals including BLOOD, Leukemia, Leukemia and Lymphoma, Experimental Hematology, Haematologica, Journal of Bone and Mineral Research, Leukemia, Cell Stem Cell, Clinical Cancer Research, Cancer Research, International Journal of Cancer, Bone, FASEB Journal. I am also regularly asked to review applications for a number of funding bodies including the NHMRC, Cancer Council of South Australia, Cure Cancer Australia and Leukaemia Research Fund (UK). Most recently, I was approached by the Wiley-Blackwell publishing house to assess the merits of publication of a book entitled: “Stem Cells: Science and Business Strategies” by A. Vertes et al.

As further evidence of my scientific standing, I have served on organising committees involved in staging both national and international scientific meetings including; the 2004 Hanson Symposium Stem Cell Meeting (Adelaide, SA, 2004); the 10th International Myeloma Congress (Sydney, NSW, 2005); the Clare Bone Meeting (Clare Valley, SA, 2006). I represented the Centre for Cancer Biology (CCB) as a Subject Matter Expert (SME) charged with the role of identifying the facilities requirements for the South Australian Health and Medical Research Institute (SAHMRI). Finally, I have served on the Fellowships and Scholarships Committee for the Leukaemia Foundation of Australia.

Clinical Outcomes of Research

As a member of MSAG, I have provided guidance on both myeloma and supportive treatment strategies and have co-authored guidelines for the safe use of bisphosphonates (Dickinson M et al, Intern Med J. 2009. May;39(5):304-16) and Clinical Practice Guidelines (Quach H et al, in preparation, 2010). Furthermore, my work has raised the awareness amongst clinicians of the importance of routine examination of CTX levels in patients. CTX (the C-telopeptide of the α1 chain of collagen type 1), a reliable marker of bone turnover, is now being used locally as a routine test for all myeloma patients at diagnosis and restaging. CTX, when used in conjunction with paraprotein levels and bone marrow assessment can detect early progression of myeloma. This is a palpable achievement and one that has led to better outcomes for patients.

As a co-inventor of the Mesenchymal Progenitor Cell (MPC) cellular therapy, I have been instrumental in developing a therapy that is likely to have a significant impact in the areas of spinal fusion, osteoarthritis, congestive heart failure, heart attacks, eye diseases, diabetes, and bone marrow repair.

Patents

I am a co-inventor of 8 patents that describe the isolation and composition of matter of mesenchymal precursor cells (MPC), a unique population of adult stem cells with tissue reparative properties. This family of patents were assigned to Angioblast Systems Inc., New York, USA in November, 2004 facilitating the formation of Mesoblast Ltd, an Australian Stock Exchange listed company. In 2010, Mesoblast acquired Angioblast Systems Inc forming the Mesoblast Group.

Year Patent Number Patent Office Status
Patents
2008 US 61/189,349 United States of America Under Examination
2006 PCT/AU2006/000494 United States of America Under Examination
2004 PCT/AU2005/001445 United States of America Granted
2004 PCT/AU2005/000953 United States of America Granted
2003 WO 2004/085630 United States of America Granted
2003 WO 2004/084921 Australia Granted
1999 WO 01/04268A1 United States of America Granted
1997 WO9707204 United States of America Granted
1997 JP9188700 Japan Granted
    Expand
  • Appointments

    Date Position Institution name
    2015 Principal Senior Research Fellow SAHMRI
    2012 Associate Dean, Research University of Adelaide
    2012 Professor of Experimental Haematology University of Adelaide
    2011 Affiliate Professor University of Adelaide
    2010 Chief Medical Scientist and Head of the Research Unit SA Pathology / Institute of Medical and Veterinary Science
    2010 ASH Abstract Reviewer American Society of Haematology
    2008 - 2012 Research Manager SA Pathology/Institute of Medical and Veterinary Science
    2008 - 2012 Co-Head, Regenerative Medicine Program Institute of Medical and Veterinary Science
    2007 - 2012 Chief Medical Scientist, Laboratory Head and Research Manager SA Pathology/Institute of Medical and Veterinary Science
    2007 - 2010 Affiliate Associate Professor University of Adelaide
    2006 - 2012 Head of the Myeloma Research Program Institute of Medical and Veterinary Science
    2005 Site reviewer University of Sheffield, Leukemia Foundation - United Kingdom
    2004 - 2006 Principle Medical Scientist and Laboratory Head Institute of Medical and Veterinary Science/Hanson Institute
    2000 - 2003 Senior Medical Scientist Institute of Medical and Veterinary Science/Hanson Institute
    1997 - 1999 NH&MRC Research Officer Institute of Medical and Veterinary Science
  • Awards and Achievements

    Date Type Title Institution Name Country Amount
    1999 Award Young Investigator Award Hanson Centre for Cancer Research Australia
    1998 Award Johnson and Johnson Young Investigator award Australian and New Zealand Orthopaedics Research Society Australia
    1992 Award Postgraduate Scholarship Award University of Adelaide Australia
  • Education

    Date Institution name Country Title
    1997 University of Adelaide Australia PhD
    1992 University of Adelaide Australia Honours (First Class)
    1991 University of Adelaide Australia BSc (Hons)
  • Research Interests

Research Funding

Since establishing my laboratory in 2000, I have received competitive research funding of more than AUD$15,019,583 and AUD$2,835,000 in infrastructure funding. Of note, as a CI, I have been awarded a total of 19 NHMRC grants valued in excess of AUD$9,725,058, 1 Cancer Australia grant and 1 International Leukemia Lymphoma Society (US) grant. Furthermore, I have received industry funding of AUD$5 million from sources including Mesoblast, Celgene, Novartis, Zimmer and Johnson & Johnson. A list of the NH&MRC, ARC and other awarded grants are provided below.

Grant Title Funding Initiative Role First Year Funded Number of Years Total Amount ($) of Grant
Summary of NH&MRC Funding

Targeting skeletal mTORC1 as a novel approach for the treatment of diet-induced insulin resistance

Research Support

Project Grant

CIA

2016

3

586,979.00

Why is the bone marrow a “hot-spot” for myeloma plasma cell metastasis: are there Gremlins in the system?

Research Support

Project Grant

CIA

2016

3

651,979.00

The role of ephrinB1 reverse signalling in osteogenic differentiation during skeletal development and osteoporosis

Research Support

Project Grant

CIB

2015

3

548,347.00

Understanding clonal evolution in multiple myeloma

Research Support

Project Grant

CIA

2014

3

647,111.00

Twist-1 inhibits MSC osteoblast differentiation during osteoporosis

Research Support

Project Grant

CIB

2013

3

466,044.00

Is mTOR a novel target for the treatment of osteoporosis?

Research Support

Project Grant

CIA

2012

3

543,675.00

EphB-ephrinB mediates MSC bone regeneration

Research Support

Project Grant

CIB

2012

3

591,010.00

The Role of Hypoxia and Myeloma Disease Progression

Research Support

Project Grant

CIA

2010

3

594,582.00

Twist-1 Regulation of MSC Growth and Development

Research Support

Project Grant

CIB

2010

3

594,582.00

Novel strategies for the treatment of bone cancer

Research Support

Project Grant

CIC

2009

3

456,304.00

Control of premature bony fusion in skull development

Research Support

Project Grant

CIC

2008

3

555,855.00

Role of TWEAK in bone remodelling

Research Support

Project Grant

CIE

2007

3

566,947.00

The role of factors that regulate early processes of bone cell development

Research Support

Project Grant

CIB

2007

3

485,929.00

Chemokines and Myeloma Disease Progression

Research Support

Project Grant

CIA

2007

3

665,897.00

The role of human osteoblasts in osteoclast formation

Research Support

Project Grant

CIC

2004

3

436,450.00

Skeletal disease mediated by haematological malignancy

Research Support

Project Grant

CIA

2004

3

432,750.00

The cells and molecules involved in the formation and activity of human osteoclasts

Research Support

Project Grant

CID

2001

3

326,036.00

Drug resistance in leukaemia

Research Support

Project Grant

CIC

2001

3

362,545.00

The Molecular Mechanisms of Bone Destruction in Multiple Myeloma

Research Support

Project Grant

CIA

2001

3

212,036.00

Grant Title Funding Source Role First Year Funded Number of Years Total Amount ($) of Grant
Summary of Other Funding

Skeletal endocrine signalling in the regulation of glucose metabolism

Research Support

Australian Research Council

CIA

2016

3

379,400.00

A Tough Resilin based Hydrogel Platform for Repair and Regeneration

Research Support

Australian Research Council

CIB

2016

3

358,000.00

Tyrosine Kinase Inhibition as a Potential Modality to Control Osteolytic Bone Disease: A New Role for Imatinib Mesylate and Second Generation Bcr-Abl Inhibitors

Industry Research Support

Novartis Pharma-ceuticals International

CIA

2007

3

470,000.00

Efficacy of Targeting the mTOR and PI3 Kinase Pathways as a Treatment Modality for Myeloma

Industry Research Support

Novartis Pharma-ceuticals International

CIA

2011

1

65,000.00

Development of a Comprehensive Data Base for Myeloma and Related Disorders

Industry Support

Celgene Australia

CIB

2010

2

120,000.00

Seed Grant for the Establishment of a Multiple Myeloma and Related Disorders Database

Research Support

Cancer Council of South Australia

CIB

2010

1

35,000.00

Abl Kinase Inhibition as a Novel Therapy for Myeloma-Associated Bone Loss

Research Support

Leukemia & Lymphoma Society - TRP

CIA

2009

3

750,000.00

Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients?

Research Support

Cancer Australia and Leukaemia Foundation

CIA

2010

3

528,666.00

Abl Kinase Inhibition as a Novel Therapy for Malignancy-Associated Bone Loss

Research Support

Cancer Council of South Australia

CIA

2009

1

93,000.00

Does Modifying the bone marrow stromal micro-environment alter the disease course of multiple myeloma?

Research Support

Cancer Council of South Australia

CIA

2009

1

99,171.00

Coopertaing genetic changes that drive MM development: the role of SAMSN1 and GLIPR1 tumour suppressor gene

Research Support

Cancer Council of South Australia

CIA

2015

1

75,000.00

Is mTOR a novel target for the treatment of osteoporosis?

Research Support

Research, Robinson Institute Collaborative Grant

CIA

2011

1

75,000.00

Understanding the mechanisms of aberrant bone formation in Saethre-Chotzen syndrome patients with Twist-1 mutations

Research Support

Research, Robinson Institute Collaborative Grant

CIB

2013

1

65,000.00

Understanding the mechanisms of aberrant bone formation in Saethre - Chotzen syndrome patients with Twist-1 mutations

Research Support

Project Grant

CIB

2007

3

485,929.00

Understanding clonal evolution in multiple myeloma

Research Support

Ray and Shirl Norman Trust- HSCGB

CIA

2014

3

300,000.00

South Australian Blood Cancer Tumour Bank

Infra-structure Support

SA Cancer Research, Medvet, Community donor

CID

2013

3

980,000.00

Minimal residual disease (MRD) detection in Multiple Myeloma (MM) patients in complete remission post-autograft: correlation with risk of relapse?

Research Support

SA Pathology RAH Contributing Haematologists’ Committee Fund

CIB

2015

1

30,000.00

Australian Cancer Research Foundation

South Australian Innovative Cancer Imaging And Therapeutics Facility

 

Infra-structure Support

Australian Cancer Research Foundation

CIC

2013

1

1,800,000.00

Bone Marrow Recovery in Acute Lymphoblastic Leukaemia

Research Support

Women’s and Children’s Health Foundation

CIA

2015

2

226,426.00

An improved technology for isolating human adult stem cells for regenerative therapies

Research Support

Adelaide Research and Innovation- Commercial Accelerator Scheme Fund

CIA

2013

1

100,000.00

Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease?

Research Support

RAH/IMVS Clinical Research Grants

CIA

2004

1

18, 500

 

The Identification and Characterization of Novel Regulators of Mesenchymal Stem Cell Differentiation and Lineage Commitment

Industry Support

Zymogenetics Inc., Seattle, Washington

CIA

1999

1

90,000.00

Characterisation of Novel Drug-Resistance Proteins in Human Leukaemic Cells

Industry Support

Medvet Pty Ltd

CIC

2000

1

110,000.00

Novel Interaction of the Epidermal Growth Factor-Like Protein DLK with the Growth Arrest-Specific Gene Product GAS-1: Implications for Adipocyte Differentiation

Research Support

IMVS/RAH Research Fund

CIB

2001

1

11,000.00

Characterisation of RANKL and OPG production by human osteoblastic cells

Industry Support

Ely Lilly

CIB

2002

1

20,000.00

Utilisation of human osteoblast and osteoclast co-culture models to study anti-resorptive and anabolic agents

Industry Support

Ely Lilly

CIC

2004

1

15,000.00

 

Tantalum and osteointegration

Industry Support

Zimmer

CIC

2002

1

45,000.00

Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease?

Research Support

Royal Adelaide Hospital-IMVS Research Fund-Clinical Project Grants

CIA

2004

1

23,500.00

Mechanisms of Increased Microvessel Density (MVD) In Multiple Myeloma

Research Support

IMVS-Contributing Haematologist Committee Fund

CIA

2004

1

36,000.00

The Use of Aptamer-Based technologies to Identify Immuno-dominant Epitopes of Factor VIII Which are Responsible for the Development of Anti-Factor VIII Antibodies (Inhibitors)

Research Support

IMVS-Contributing Haematologist Committee Fund

CIA

2005

1

30,000.00

Can The Level of Stromal-Derived Factor-1 (SDF-1α) In Myeloma Patients Predict if They Will Develop Osteolytic Bone Disease?

Research Support

Cancer Council South Australia

CIA

2005

1

149,416.00

The Efficacy of Mesenchymal Precursor Cells to Repair Cardiac Defects

Industry Support

Angioblast Systems, Ltd

CIA

2003

2

100,000.00

Development of Strategies For The Therapeutic Use of Mesenchymal Precursor Cells For Cartilage Repair

Industry Support

Mesoblast Ltd

CIB

2006

2

320,692.00

Evaluation of the safety and efficacy of Allogeneic Mesenchymal Progenitor Cells (MPC) for the repair of critical size defects in an ovine tibial model

Industry Support

Mesoblast Ltd

CIB

2006

1

725,000.00

A Preclinical trial of the potential for cultured mesenchymal precursor cells to restore extracellular matrix and normal mechanical function to degenerate intervertebral discs

Industry/

Research Support

Mesoblast Ltd/ AusIndustry Grant

CIC

2006

2

794,850.00

Research and Services Agreement

Industry/

Research Support

Angioblast Ltd/ Mesoblast Ltd

CIB

2003

3

300,000.00

BIR (Bortezomib Induction and Reinduction) Study

Clinical Trial and Research Support

Johnson & Johnson

CIB

2006

2

445,875.00

Kodak chemiluminescence and gel imaging system (4000MM Pro Image Station).

 

Infra-structure Support

University of Adelaide/NH&MRC Equipment Grant

CIF

2008

1

55,000.00

As a former fulltime Medical Scientist in the Department of Haematology, SA Pathology/Institute of Medical and Veterinary Science and Level E Affiliate Titleholder in the School of Medicine, Faculty of Health Science, University of Adelaide, I provided leadership in teaching and supervision in my daily interactions with post-doctoral scientists, research assistants, undergraduate, graduate and post-graduate students. Furthermore, during this period, I provided numerous guest lectures (BBTech students, Uni SA; BHlthSci and MBBS, Uni Adelaide) and successfully mentored numerous honours, masters, PhD and medical students (as part of Department of Medicine’s 4th Year Research Program).

In addition to graduate and post-graduate teaching, since joining the University of Adelaide as Professor of Experimental Haematology, I present undergraduate lectures in courses offered by the Faculty of Health Science ([FHS] Medicine, Physiology, Anatomy and Pathology and Dentistry), Faculty of Science ([FS] Masters program, stem cells) and the University of Sydney (tissue engineering). I provide Honours workshops relating to thesis writing, career opportunities and career development. I also host Physiology III (BHlthSci, FHS) and Principals and Practice of Research III (BSc Advanced, FS) students in my laboratory for small group discovery and research training.

    Expand
  • Current Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2019 Principal Supervisor Novel Treatments with Antibacterial and Wound-healing Properties Doctor of Philosophy under a Jointly-awarded Degree Agreement with Doctorate Full Time Mrs Laurine Dorothea Kaul
    2019 Principal Supervisor The roles of the Tam Receptor Family in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Justine Rachel Clark
    2019 Co-Supervisor Deciphering the specific roles of HIF1 and HIF2 in multiple myeloma Master of Philosophy Master Full Time Ms Carla Ruth Gallasch
    2019 Principal Supervisor The Yin and Yang of Myeloma Development: The Role of the Bone Marrow Microenvironment in Plasma Cell Dormancy and Activation Doctor of Philosophy Doctorate Full Time Miss Natalya Plakhova
    2017 Principal Supervisor Investigation of the competing effects of the CXCL12/CXCR4 and CCL3/CCR1 chemokine axes in the dissemination and migration of multiple myeloma plasma cells Doctor of Philosophy Doctorate Full Time Miss Mara Natasha Zeissig
    2017 Co-Supervisor Elucidating the Roles HIFI/HIFI2 on Multiple Myeloma Using an Inducible CRISPR/Cas9 System Master of Philosophy Master Full Time Mr Yu Chinn Joshua Chey
    2017 Principal Supervisor The role of osteoblast-mTORC1 in the regulation of glucose metabolism and male fertility Doctor of Philosophy Doctorate Full Time Miss Pawanrat Tangseefa
    2017 Principal Supervisor Investigating the Role of Resident Bone Macrophages in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mrs Khatora Shanae Opperman
    2015 Co-Supervisor High Cell Density Proliferation of Human Induced Pluripotent Stem Cells Doctor of Philosophy Doctorate Full Time Mr Jiabin Zhang
    2015 Principal Supervisor Cooperating Genetic Changes that Drive Myeloma Development - The Role of the Samsn 1 and GLIPRI Tumour Suppressor Genes Doctor of Philosophy Doctorate Full Time Ms Natasha Friend
  • Past Higher Degree by Research Supervision (University of Adelaide)

    Date Role Research Topic Program Degree Type Student Load Student Name
    2014 - 2018 Principal Supervisor A Genomic Approach Towards an Understanding of Clonal Evolution and Disease Progression in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Ankit Kumar Dutta
    2013 - 2017 Principal Supervisor The Role of TWIST1 in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Chee Man Cheong
    2012 - 2018 Principal Supervisor N-cadherin: Regulation, Role and Therapeutic Targeting in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Mr Krzysztof Mrozik
    2011 - 2014 Co-Supervisor Mesenchymal Stem Cells for the Treatment of Myocardial Infarction-Induced Ventricular Dysfunction Doctor of Philosophy Doctorate Full Time Dr James David Richardson
    2011 - 2018 Co-Supervisor Investigating the Role of HIF-1 and HIF-2 Transcription Factors in Multiple Myeloma Doctor of Philosophy Doctorate Full Time Miss Natalia Magdalena Martin
    2010 - 2018 Principal Supervisor The Role of mTORC1 in Mesenchymal Stem Cell Fate Determination, Osteoblast Differentiation and Skeletal Development Doctor of Philosophy Doctorate Part Time Ms Mary Patricia Matthews
    2009 - 2013 Co-Supervisor The Role of TWIST-1 in the Regulation of Mesenchymal Stem Cell Growth, Fracture Repair and Bone Loss Doctor of Philosophy Doctorate Full Time Mr Lachlan Cooper
    2007 - 2011 Co-Supervisor Cell Lineage, Cell Maturity and BCR-ABL: Factors Which Influence Imatinib Uptake in Chronic Myeloid Leukaemia Doctor of Philosophy Doctorate Full Time Ms Jane Engler
    2007 - 2010 Principal Supervisor The Effects of Tyrosine Kinase Inhibition on Bone Remodelling Doctor of Philosophy Doctorate Full Time Dr Kate Vandyke
    2006 - 2010 Co-Supervisor The Cardiovascular Reparative Properties of Bone Marrow Mesenchymal Precursor Cells Doctor of Philosophy Doctorate Full Time APrf Peter Psaltis
    2005 - 2009 Principal Supervisor Molecular and Cellular Mechanisms of Increased Angiogenesis in Multiple Myeloma: A Role for CXCL12 Doctor of Philosophy Doctorate Full Time Mrs Sally Martin
    2005 - 2012 Co-Supervisor Cellular and Molecular Mechanisms Involved in the Repair of the Injured Growth Plate in Young Rats Doctor of Philosophy Doctorate Full Time Ms Carmen Macsai
    2004 - 2008 Co-Supervisor Factors which Impact on the Response of CML Patients to ABL Kinase Inhibitor Therapy: A Study of Imatinib and Nilotinib Doctor of Philosophy Doctorate Part Time Prof Deborah Lee White
    2002 - 2004 Principal Supervisor Mechanisms of Skeletal Disease Mediated by Haematological Malignancies Doctor of Philosophy Doctorate Full Time Miss Beiqing Pan
    2001 - 2002 Principal Supervisor CLINICAL MEDICINE Master of Medical Science Master Full Time Miss Beiqing Pan
    Expand
  • Board Memberships

    Date Role Board name Institution name Country
    2016 - ongoing ARCPOH Expert Advisory Committee University of Adelaide
    2015 - ongoing Member Board of Directors Colgate Australian Clinical Dental Research Centre, University of Adelaide Australia
    2014 - ongoing Member Advisory Board Robinson Research Institute (RRI), University of Adelaide Australia
  • Committee Memberships

    Date Role Committee Institution Country
    2016 - ongoing Member National Health and Medical Research Council NHMRC Assigners Academy Australia
    2015 - ongoing Member National Health and Medical Research Council NHMRC Assigners Academy Australia
    2014 - 2015 Chair Research Committee, School of Medical Science University of Adelaide Australia
    2012 - ongoing Member Bioscience Pillar Committee South Australian Health and Medical Research Institute (SAHMRI) Australia
    2012 - ongoing Member Cell Reprogramming Australia (CRA)
    2012 - ongoing Member Robinson Institute Transition Management Committee University of Adelaide Australia
    2012 - ongoing Member Leukaemia Foundation National Research Program Assessment Panel Leukaemia Foundation Australia
    2010 - 2015 Member Scientific Advisory Committee Bone Health Foundation Australia
    2010 - ongoing Member Centre for Personalised Cancer Medicine The University of Adelaide Australia
    2010 - 2013 Member Fellowships and Scholarships Committee Leukaemia Foundation of Australia Australia
    2009 - 2012 Member Medical Assessment Classification Committee SA Pathology
    2007 - 2012 Co-Chair Institutional Biosafety Committee SA Pathology/Institute of Medical and Veterinary Science Australia
    2006 - ongoing Member Medical and Scientific Advisory Group Australian Myeloma Foundation Australia
  • Memberships

    Date Role Membership Country
    2010 - ongoing Member Centre for Cancer Biology, SA Pathology Australia
    2010 - ongoing Member Centre for Stem Cell Research, University of Adelaide Australia
  • Consulting/Advisories

    Date Institution Department Organisation Type Country
    2013 - ongoing CSIRO Australia
    2010 - ongoing South Australian Health and Medical Research Institute Australia
  • Offices Held

    Date Office Name Institution Country
    2014 - ongoing NHMRC Assigners Academy National Health and Medical Research Council Australia
    2012 - ongoing Cancer Biology and Oncology GRP National Health and Medical Research Council Australia
    2011 - ongoing Reshaping the Robinson Task Force, Robinson Institute University of Adelaide Australia
    2010 - ongoing Oncology GRP National Health and Medical Research Council Australia
    2006 - ongoing Cell Biology GRP National Health and Medical Research Council Australia
  • Position: Interim Executive Dean
  • Phone: 83135193
  • Email: andrew.zannettino@adelaide.edu.au
  • Campus: North Terrace
  • Building: Helen Mayo North, floor 3
  • Room: N3 07
  • Org Unit: Health and Medical Sciences Faculty Office

Connect With Me
External Profiles

Other Links